Prespecified secondary analysis of FINEARTS-HF (5,815 participants, HF with LVEF ≥40%): finerenone increased SBP <100 mm Hg (538 vs 361; OR 1.60) and reported hypotension (225 vs 139; OR 1.67) versus placebo; benefit was not significantly modified (P interaction 0.33).
Secondary analysisn = 5,815
Foà et al. Finerenone-Related Risk of Hypotension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction